Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) and Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Risk and Volatility
Acrivon Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Astellas Pharma has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.
Valuation & Earnings
This table compares Acrivon Therapeutics and Astellas Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acrivon Therapeutics | N/A | N/A | -$60.39 million | ($2.70) | -2.00 |
| Astellas Pharma | $11.11 billion | 1.63 | $113.00 million | ($0.22) | -45.43 |
Institutional and Insider Ownership
71.6% of Acrivon Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Acrivon Therapeutics and Astellas Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acrivon Therapeutics | N/A | -47.95% | -43.73% |
| Astellas Pharma | -3.10% | 13.69% | 6.06% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Acrivon Therapeutics and Astellas Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acrivon Therapeutics | 0 | 0 | 8 | 0 | 3.00 |
| Astellas Pharma | 0 | 0 | 0 | 0 | 0.00 |
Acrivon Therapeutics presently has a consensus target price of $23.67, indicating a potential upside of 339.08%. Given Acrivon Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Acrivon Therapeutics is more favorable than Astellas Pharma.
Summary
Acrivon Therapeutics beats Astellas Pharma on 8 of the 13 factors compared between the two stocks.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
